

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

VOLUNTARY ANNOUNCEMENT

The board of directors of CANbridge Pharmaceuticals Inc. (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that CAN 103, the first domestically independently developed and manufactured class 1 innovative enzyme replacement therapy by the Group, has been successfully included in the first edition of China’s “Commercial Health Insurance Innovative Drug List” (the “**List**”), which will officially take effect on January 1, 2026.

According to the work plan issued by the National Healthcare Security Administration (“**NHSA**”), the first edition of the List primarily includes innovative drugs that exceed the “basic medical security” positioning, are temporarily ineligible for inclusion in the National Reimbursement Drug List, but feature high innovation, significant clinical value, and substantial patient benefits. It serves as a reference for China’s multi-level medical security system, including commercial health insurance and medical mutual aid programs. As previously disclosed by the NHSA, 121 drug varieties applied for inclusion in the List during the 2025 healthcare insurance negotiations, with only 24 advancing to the final negotiation stage.

CAN 103 was approved for marketing on May 13, 2025, as China’s first domestically developed and produced long-term enzyme replacement therapy for adolescents (12 years and older) and adults with Type I and Type III Gaucher disease. It is also the first innovative biologic in China to pass the segmented production inspection for biological products. On July 2, 2025, the first prescription of CAN 103 was issued at Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, marking its official entry into clinical practice and promising to significantly improve medication accessibility for domestic patients.

The Company considers the inclusion of CAN 103 in the List as a milestone achievement for the Group as it will ensure that Gaucher disease patients have access to affordable, safe, and effective domestic enzyme replacement therapy, receiving broader and more comprehensive treatment coverage.

Driven by the healthcare security system's support for the high-quality development of the pharmaceutical industry, the Group will continue to deepen the domestic R&D, production, commercialization, and accessibility of rare disease drugs, bringing more innovative treatment options to Chinese patients.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, December 8, 2025

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.